FibroBiologics says fibroblast spheroids drive burn healing, reduce scarring

FibroBiologics (FBLG) announced preclinical results suggesting that topical treatment with human dermal fibroblast spheroids may reprogram the burn wound environment by dampening harmful inflammation, reshaping immune cell behavior, and reducing markers of scar-forming activity, within eight days of injury. “These preclinical results are an important validation of our strategy to broaden the FibroBiologics wound care platform beyond our core indications. Fibroblasts play an essential role in wound healing, and what we are seeing here suggests they may be uniquely positioned to address the pathological inflammation and scarring that define burn injuries,” said Pete O’Heeron, founder and CEO.